While this line of investigation supports strong pre‐clinical data for trials of Ang‐(1‐7) in human RDEB, the potential disease‐modifying benefit of immunomodulatory approaches is also supported. This evidence concerns the gene ANG and recessive dystrophic epidermolysis bullosa.